Cat. No.
MABL-3696
Application
WB, ELISA, FC
Isotype
Engineer antibody
Species Reactivity
Human
Clone No.
2F8 (Zalutumumab; HuMax-EGFR)
From
Recombinant Antibody
Specificity
This antibody binds domain III of the human epidermal growth factor receptor (EGFR).
Alternative Names
ERBB1; ERBB; Erb-B2; HER1; Epidermal growth factor receptor; Proto- oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1
UniProt
P00533
Immunogen
The original monoclonal antibody was generated by immunizing HuMAb mice with alternating A431 cells and purified EGFR administration.
Application Notes
This antibody blocks the binding of EGF and TGF-α to the EGFR. At saturating concentrations, 2F8 completely blocked EGF-R signaling and inhibited the in vitro proliferation of EGF-R- overexpressing A431 cells. At much lower concentrations, associated with low receptor occupancy, 2F8 induced efficient Ab-dependent cell-mediated cytotoxicity (ADCC) in vitro. In vivo studies showed potent antitumor effects in models with A431 tumor xenografts in athymic mice. Flow cytometry was used to analyze the binding of mAb 2F8 to EGFR overexpressing A431 cells. mAb 2F8 was found to bind to membrane-associated EGF-R with an EC50 of approximately 1 µg/ml (7 nM). The ability of mAb 2F8 to block ligand-induced receptor phosphorylation was determined using immunoblotting. ELISA was used to determine whether mAb 2F8 had a functional C1q binding cite (Bleeker et al., 2004).
Antibody First Published
Bleeker et al. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol. (2004); 173(7):4699-707. PMID:15383606
Note on publication
Describes the characterization of this antibody.
Size
100 μg Purified antibody.
Concentration
1 mg/ml.
Purification
Protein A affinity purified
Buffer
PBS with 0.02% Proclin 300.
Storage Recommendation
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C.
